FDA Approves BARACLUDE — E.R. Squibb & Sons, L.L.C.
E.R. Squibb & Sons, L.L.C. received FDA approval for Baraclude (entecavir) oral tablets in March 2005, positioning it as a potent therapeutic option for the chronic management of hepatitis B that is expected to broaden Brewer's market share in the antiviral segment.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day